"valign=\\\"top\\\">326</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">337</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">HbA1c (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.5</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 52<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.4</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Difference from insulin glargine<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">--</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.7<span class=\\\"Sup\\\">c</span><br/>(-0.9, -0.6)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.9<span class=\\\"Sup\\\">c</span><br/>(-1.1, -0.8)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.0<span class=\\\"Sup\\\">c</span><br/>(-1.2, -0.9)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Patients (%) achieving HbA1c &lt;7%<span class=\\\"Sup\\\">d</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">49</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">75<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">83<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">85<span class=\\\"Sup\\\">c</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Fasting Serum Glucose (mg/dL)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">168</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">172</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">176</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">174</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 52<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-49</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-44</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-50</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-55</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Body Weight (kg)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">90.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">90.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">90.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">90.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 52<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-6.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-8.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-10.6</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Difference from insulin glargine<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">--</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-8.1<span class=\\\"Sup\\\">c</span><br/>(-8.9, -7.3)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-10.6<span class=\\\"Sup\\\">c</span><br/>(-11.4, -9.8)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-12.2<span class=\\\"Sup\\\">c</span><br/>(-13.0, -11.5)</td></tr></tbody></table></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s80\\\"></a><a name=\\\"section-13.4\\\"></a><p></p><h2>14.4 MOUNJARO Use in Combination with Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus</h2><p class=\\\"First\\\">SURPASS-5 (NCT04039503) was a 40-week double-blind trial that randomized 475 patients with type 2 diabetes mellitus with inadequate glycemic control on insulin glargine 100 units/mL, with or without metformin, to MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or placebo. The dose of background insulin glargine was adjusted using a treat-to-target algorithm based on self-measured fasting blood glucose values, targeting &lt;100 mg/dL.</p><p>Patients had a mean age of 61 years, and 56% were men. The mean duration of type 2 diabetes mellitus was 13.3 years, and the mean baseline BMI was 33 kg/m<span class=\\\"Sup\\\">2</span>. Overall, 80% were White, 1% were Black or African American, and 18% were Asian; 5% identified as Hispanic or Latino ethnicity.</p><p>The mean dose of insulin glargine at baseline was 34, 32, 35, and 33 units/day for patients receiving MOUNJARO 5 mg, 10 mg, 15 mg, and placebo, respectively. At randomization, the initial insulin glargine dose in patients with HbA1c ≤8.0% was reduced by 20%. At week 40, mean dose of insulin glargine was 38, 36, 29, and 59 units/day for patients receiving MOUNJARO 5 mg, 10 mg, 15 mg, and placebo, respectively.</p><p>Treatment with MOUNJARO 5 mg once weekly, 10 mg once weekly and 15 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with placebo (see <a href=\\\"#t7\\\">Table 7</a>).</p><a name=\\\"t7\\\"></a><table width=\\\"100%\\\"><caption><span>Table 7: Results at Week 40 in a Trial of MOUNJARO Added to Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus</span></caption><col align=\\\"left\\\" width=\\\"44.449%\\\"/><col align=\\\"left\\\" width=\\\"13.183%\\\"/><col align=\\\"left\\\" width=\\\"14.123%\\\"/><col align=\\\"left\\\" width=\\\"14.123%\\\"/><col align=\\\"left\\\" width=\\\"14.123%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 4%, 1%, 0%, and 1% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c endpoint was missing for 2%, 6%, 3%, and 7% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> p&lt;0.001 (two-sided) for superiority vs. placebo, adjusted for multiplicity.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>5 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>10 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>15 mg</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Modified Intent-to-Treat (mITT) Population (N)<span class=\\\"Sup\\\">a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">119</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">116</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">118</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">118</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">HbA1c (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.2</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 40<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">--</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.2<span class=\\\"Sup\\\">c</span><br/>(-1.5, -1.0)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.5<span class=\\\"Sup\\\">c</span><br/>(-1.8, -1.3)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.5<span class=\\\"Sup\\\">c</span><br/>(-1.7, -1.2)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Patients (%) achieving HbA1c &lt;7%<span class=\\\"Sup\\\">d</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">35</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">87<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">90<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">85<span class=\\\"Sup\\\">c</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Fasting Serum Glucose (mg/dL)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">164</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">163</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">163</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">160</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 40<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-39</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-58</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-64</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-63</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">--</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-19<span class=\\\"Sup\\\">c</span><br/>(-27, -11)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-25<span class=\\\"Sup\\\">c</span><br/>(-32, -17)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-23<span class=\\\"Sup\\\">c</span><br/>(-31, -16)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Body Weight (kg)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">94.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">95.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">94.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">96.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 40<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-5.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-7.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-8.8</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">--</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-7.1<span class=\\\"Sup\\\">c</span><br/>(-8.7, -5.4)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-9.1<span class=\\\"Sup\\\">c</span><br/>(-10.7, -7.5)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-10.5<span class=\\\"Sup\\\">c</span><br/>(-12.1, -8.8)</td></tr></tbody></table></div></section>\",\n            \"howSupplied\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34069-5\\\"><a name=\\\"s82\\\"></a><a name=\\\"section-14.1\\\"></a><p></p><h2>16.1 How Supplied</h2><p class=\\\"First\\\">MOUNJARO is a clear, colorless to slightly yellow solution available in cartons containing 4 pre-filled single-dose pens or 1 single-dose vial as follows:</p><table width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"30.823%\\\"/><col align=\\\"left\\\" width=\\\"37.054%\\\"/><col align=\\\"left\\\" width=\\\"32.123%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Total Strength per Total Volume</span></td><td align=\\\"left\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold Underline\\\">Pen </span><span class=\\\"Bold\\\">NDC</span></td><td align=\\\"left\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold Underline\\\">Vial </span><span class=\\\"Bold\\\">NDC</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">2.5 mg/0.5 mL</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-1506-80</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-1152-01</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">5 mg/0.5 mL</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-1495-80</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-1243-01</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">7.5 mg/0.5 mL</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-1484-80</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-2214-01</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">10 mg/0.5 mL</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-1471-80</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-2340-01</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">12.5 mg/0.5 mL</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-1460-80</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-2423-01</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">15 mg/0.5 mL</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-1457-80</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0002-3002-01</td></tr></tbody></table></section>\",\n            \"useInSpecificPopulations\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43684-0\\\"><a name=\\\"s35\\\"></a><a name=\\\"section-8\\\"></a><p></p><h1>8 USE IN SPECIFIC POPULATIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42228-7\\\"><a name=\\\"s36\\\"></a><a name=\\\"section-8.1\\\"></a><p></p><h2>8.1 Pregnancy</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s37\\\"></a><a name=\\\"section-8.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Risk Summary</span></p><p>Available data with MOUNJARO use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy <span class=\\\"Italics\\\">(see Clinical Considerations)</span>. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy. MOUNJARO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p>In pregnant rats administered tirzepatide during organogenesis, fetal growth reductions and fetal abnormalities occurred at clinical exposure in maternal rats based on AUC. In rabbits administered tirzepatide during organogenesis, fetal growth reductions were observed at clinically relevant exposures based on AUC. These adverse embryo/fetal effects in animals coincided with pharmacological effects on maternal weight and food consumption <span class=\\\"Italics\\\">(see Data)</span>.</p><p>The estimated background risk of major birth defects is 6–10% in women with pre-gestational diabetes with an HbA1c &gt;7% and has been reported to be as high as 20–25% in women with an HbA1c &gt;10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s38\\\"></a><a name=\\\"section-8.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Clinical Considerations</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s39\\\"></a><a name=\\\"section-8.1.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Disease-Associated Maternal and/or Embryo/Fetal Risk</span></p><p>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s40\\\"></a><a name=\\\"section-8.1.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Data</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s41\\\"></a><a name=\\\"section-8.1.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Animal Data</span></p><p>In pregnant rats given twice weekly subcutaneous doses of 0.02, 0.1, and 0.5 mg/kg tirzepatide (0.03-, 0.07-, and 0.5-fold the MRHD of 15 mg once weekly based on AUC) during organogenesis, increased incidences of external, visceral, and skeletal malformations, increased incidences of visceral and skeletal developmental variations, and decreased fetal weights coincided with pharmacologically-mediated reductions in maternal body weights and food consumption at 0.5 mg/kg. In pregnant rabbits given once weekly subcutaneous doses of 0.01, 0.03, or 0.1 mg/kg tirzepatide (0.01-, 0.06-, and 0.2-fold the MRHD) during organogenesis, pharmacologically-mediated effects on the gastrointestinal system resulting in maternal mortality or abortion in a few rabbits occurred at all dose levels. Reduced fetal weights associated with decreased maternal food consumption and body weights were observed at 0.1 mg/kg. In a pre- and post-natal study in rats administered subcutaneous doses of 0.02, 0.10, or 0.25 mg/kg tirzepatide twice weekly from implantation through lactation, F<span class=\\\"Sub\\\">1</span> pups from F<span class=\\\"Sub\\\">0</span> maternal rats given 0.25 mg/kg tirzepatide had statistically significant lower mean body weight when compared to controls from post-natal day 7 through post-natal day 126 for males and post-natal day 56 for females.</p></div></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"77290-5\\\"><a name=\\\"s42\\\"></a><a name=\\\"section-8.2\\\"></a><p></p><h2>8.2 Lactation</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s43\\\"></a><a name=\\\"section-8.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Risk Summary</span></p><p>There are no data on the presence of tirzepatide in animal or human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for MOUNJARO and any potential adverse effects on the breastfed infant from MOUNJARO or from the underlying maternal condition.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"77291-3\\\"><a name=\\\"s44\\\"></a><a name=\\\"section-8.3\\\"></a><p></p><h2>8.3 Females and Males of Reproductive Potential</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s45\\\"></a><a name=\\\"section-8.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Contraception</span></p><p>Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO <span class=\\\"Italics\\\">[see Drug Interactions (<a href=\\\"#s34\\\">7.2</a>) and Clinical Pharmacology (<a href=\\\"#s54\\\">12.2</a>, <a href=\\\"#s59\\\">12.3</a>)].</span></p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"34081-0\\\"><a name=\\\"s46\\\"></a><a name=\\\"section-8.4\\\"></a><p></p><h2>8.4 Pediatric Use</h2><p class=\\\"First\\\">Safety and effectiveness of MOUNJARO have not been established in pediatric patients.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"34082-8\\\"><a name=\\\"s47\\\"></a><a name=\\\"section-8.5\\\"></a><p></p><h2>8.5 Geriatric Use</h2><p class=\\\"First\\\">In the pool of seven clinical trials, 1539 (30.1%) MOUNJARO-treated patients were 65 years of age or older, and 212 (4.1%) MOUNJARO-treated patients were 75 years of age or older at baseline.</p><p>No overall differences in safety or efficacy were detected between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"88828-9\\\"><a name=\\\"s48\\\"></a><a name=\\\"section-8.6\\\"></a><p></p><h2>8.6 Renal Impairment</h2><p class=\\\"First\\\">No dosage adjustment of MOUNJARO is recommended for patients with renal impairment. In subjects with renal impairment including end-stage renal disease (ESRD), no change in tirzepatide pharmacokinetics (PK) was observed <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s59\\\">12.3</a>)]</span>. Monitor renal function when initiating or escalating doses of MOUNJARO in patients with renal impairment reporting severe adverse gastrointestinal reactions <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s14\\\">5.5</a>)].</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"88829-7\\\"><a name=\\\"s49\\\"></a><a name=\\\"section-8.7\\\"></a><p></p><h2>8.7 Hepatic Impairment</h2><p class=\\\"First\\\">No dosage adjustment of MOUNJARO is recommended for patients with hepatic impairment. In a clinical pharmacology study in subjects with varying degrees of hepatic impairment, no change in tirzepatide PK was observed <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s59\\\">12.3</a>)]</span>.</p></div></section>\",\n            \"description\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34089-3\\\"><a name=\\\"s51\\\"></a><a name=\\\"section-10\\\"></a><p></p><h1>11 DESCRIPTION</h1><p class=\\\"First\\\">MOUNJARO (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a once weekly GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C<span class=\\\"Sub\\\">225</span>H<span class=\\\"Sub\\\">348</span>N<span class=\\\"Sub\\\">48</span>O<span class=\\\"Sub\\\">68</span>.</p><p>Structural formula:</p><div class=\\\"Figure\\\"><a name=\\\"f01\\\"></a><img alt=\\\"Structural Formula\\n\\\" src=\\\"moun-uspi-chem-struc.jpg\\\"/></div><p>MOUNJARO is a clear, colorless to slightly yellow, sterile, preservative-free solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. MOUNJARO has a pH of 6.5 – 7.5.</p></section>\",\n            \"nonclinicalToxicology\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43680-8\\\"><a name=\\\"s71\\\"></a><a name=\\\"section-12\\\"></a><p></p><h1>13 NONCLINICAL TOXICOLOGY</h1><div class=\\\"Section\\\" data-sectioncode=\\\"34083-6\\\"><a name=\\\"s72\\\"></a><a name=\\\"section-12.1\\\"></a><p></p><h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p class=\\\"First\\\">A 2-year carcinogenicity study was conducted with tirzepatide in male and female rats at doses of 0.15, 0.50, and 1.5 mg/kg (0.1-, 0.4-, and 1-fold the MRHD of 15 mg once weekly based on AUC) administered by subcutaneous injection twice weekly. A statistically significant increase in thyroid C-cell adenomas was observed in males (≥0.5 mg/kg) and females (≥0.15 mg/kg), and a statistically significant increase in thyroid C-cell adenomas and carcinomas combined was observed in males and females at all doses examined. In a 6-month carcinogenicity study in rasH2 transgenic mice, tirzepatide at doses of 1, 3, and 10 mg/kg administered by subcutaneous injection twice weekly was not tumorigenic.</p><p>Tirzepatide was not genotoxic in a rat bone marrow micronucleus assay.</p><p>In fertility and early embryonic development studies, male and female rats were administered twice weekly subcutaneous doses of 0.5, 1.5, or 3 mg/kg (0.3-, 1-, and 2-fold and 0.3-, 0.9-, and 2-fold, respectively, the MRHD of 15 mg once weekly based on AUC). No effects of tirzepatide were observed on sperm morphology, mating, fertility, and conception. In female rats, an increase in the number of females with prolonged diestrus and a decrease in the mean number of corpora lutea resulting in a decrease in the mean number of implantation sites and viable embryos was observed at all dose levels. These effects were considered secondary to the pharmacological effects of tirzepatide on food consumption and body weight.</p></div></section>\",\n            \"instructionsForUse\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"59845-8\\\"><a name=\\\"s98\\\"></a><a name=\\\"section-18\\\"></a><p></p><h1>Mounjaro Single-Dose Vial Instructions for Use</h1><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"100%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"justify\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">INSTRUCTIONS FOR USE</span><br/><span class=\\\"Bold\\\">MOUNJARO<span class=\\\"Sup\\\">®</span> [mown-JAHR-OH]</span><br/><span class=\\\"Bold\\\">(tirzepatide)</span><br/><span class=\\\"Bold\\\">injection, for subcutaneous use</span><br/><br/><span class=\\\"Bold\\\">2.5 mg/0.5 mL single-dose vial</span><br/><span class=\\\"Bold\\\">5 mg/0.5 mL single-dose vial</span><br/><span class=\\\"Bold\\\">7.5 mg/0.5 mL single-dose vial</span><br/><span class=\\\"Bold\\\">10 mg/0.5 mL single-dose vial</span><br/><span class=\\\"Bold\\\">12.5 mg/0.5 mL single-dose vial</span><br/><span class=\\\"Bold\\\">15 mg/0.5 mL single-dose vial</span></td></tr></tbody></table><p class=\\\"First\\\"><span class=\\\"Bold\\\">Important information you need to know before injecting MOUNJARO</span></p><p><span class=\\\"Bold\\\">Read this Instructions for Use before you start taking MOUNJARO and each time you get a new vial.</span> There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.      </p><p><span class=\\\"Bold\\\">Do not share your needles or syringes with other people. You may give other people a serious infection or get a serious infection from them.</span></p><p>Talk to your healthcare provider about how to inject MOUNJARO the right way.</p><ul class=\\\"Disc\\\"><li>MOUNJARO is a single-dose vial.</li><li>MOUNJARO is used 1 time each week.</li><li>Inject under the skin (subcutaneously) only.</li><li>You or another person may inject into your stomach (abdomen) or thigh.</li><li>Another person can inject into the back of your upper arm.</li></ul><p><span class=\\\"Bold\\\">Gather supplies needed to give your injection</span></p><ul class=\\\"Disc\\\"><li>1 single-dose MOUNJARO vial</li><li>1 syringe and 1 needle, supplied separately (for example, use a 1 mL syringe and needle as recommended by your healthcare provider)</li><li>1 alcohol swab</li><li>gauze</li><li>1 sharps container for throwing away used needles and syringes. <span class=\\\"Bold\\\">See</span> “Disposing of used needles and syringes” at the end of these instructions.</li></ul><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"20.000%\\\"/><col align=\\\"left\\\" width=\\\"80.000%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"center\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Guide to parts<br/><br/>Vial</span></td><td align=\\\"center\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Needle and Syringe (not included)</span></td></tr><tr><td align=\\\"center\\\" valign=\\\"middle\\\"><a name=\\\"f34a\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-1-v1.jpg\\\"/></td><td align=\\\"center\\\" valign=\\\"middle\\\"><a name=\\\"f34b\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-2-v1.jpg\\\"/></td></tr></tbody></table><p><span class=\\\"Bold\\\">Note:</span> The needle and syringe are not included. The needle and syringe recommended by your healthcare provider may look different than the needle and syringe in this Instructions for Use.</p><p><span class=\\\"Bold\\\">Preparing to inject MOUNJARO</span></p><p><span class=\\\"Bold\\\">Remove the vial</span>  from the refrigerator.      </p><p><span class=\\\"Bold\\\">Check the vial</span> label to make sure you have the right medicine and dose, and that it has not expired.      </p><p>Make sure the medicine:</p><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"50%\\\"/><col align=\\\"left\\\" width=\\\"50%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\"><ul class=\\\"Disc\\\"><li>is not frozen</li><li>is not cloudy</li></ul></td><td align=\\\"left\\\"><ul class=\\\"Disc\\\"><li>is colorless to slightly yellow</li><li>does not have particles</li></ul></td></tr></tbody></table><p><span class=\\\"Bold\\\">Always use a new syringe and needle for each injection to prevent infections and blocked needles. Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.</span></p><p><span class=\\\"Bold\\\">Wash your hands with soap and water.</span></p><table width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"53.250%\\\"/><col align=\\\"left\\\" width=\\\"46.750%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 1:</span><br/>Pull off the plastic protective cap. <span class=\\\"Bold\\\">Do not</span> remove the rubber stopper.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><a name=\\\"f35\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-3-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 2:</span><br/>Wipe the rubber stopper with an alcohol swab.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><a name=\\\"f36\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-4-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 3:</span><br/>Remove the outer wrapping from the syringe.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><a name=\\\"f37\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-5-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 4:</span><br/>Remove the outer wrapping from the needle.<br/>The syringe that your healthcare provider recommended may have a pre-attached needle. If the needle is attached, skip to step 6.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><a name=\\\"f38\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-6-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 5:</span><br/>Place the needle on top of the syringe and turn until it is tight and firmly attached.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><a name=\\\"f39\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-7-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 6:</span><br/>Remove the needle shield by pulling straight off.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><a name=\\\"f40\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-8-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 7:</span><br/>Hold the syringe in one hand with the needle pointing up. With the other hand pull down on the plunger until the plunger tip reaches the line on the syringe indicating that 0.5 mL of air has been drawn into the syringe.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><a name=\\\"f41\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-9-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 8:</span><br/>Push the needle through the rubber stopper of the vial.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><br/><a name=\\\"f42\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-10-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 9:</span><br/>Push the plunger all the way in. This puts air into the vial and makes it easier to pull the solution from the vial.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><br/><a name=\\\"f43\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-11-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 10: </span><br/>Turn the vial and syringe upside down. Make sure that the tip of the needle is in the liquid and slowly pull the plunger down until the plunger tip is past the 0.5 mL line.<br/> If there are air bubbles, tap the syringe gently a few times to let any air bubbles rise to the top.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><a name=\\\"f44\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-12-v1.jpg\\\"/><a name=\\\"f45\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-13-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 11:</span><br/>Slowly push the plunger up until the plunger tip reaches the 0.5 mL line.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><a name=\\\"f46\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-14-v1.jpg\\\"/></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 12:</span><br/>Pull the syringe out of the rubber stopper of the vial.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><a name=\\\"f47\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-15-v1.jpg\\\"/></td></tr></tbody></table><p><span class=\\\"Bold\\\">Injecting MOUNJARO </span></p><ul class=\\\"Disc\\\"><li>Inject exactly as your healthcare provider has shown you. Your healthcare provider should tell you if you should pinch the skin before injecting.</li><li><span class=\\\"Bold\\\">Change (rotate) your injection site within the area you choose for each dose</span> to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.</li><li><span class=\\\"Bold\\\">Do not</span> inject where the skin has pits, is thickened, or has lumps.</li><li><span class=\\\"Bold\\\">Do not</span> inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.</li><li><span class=\\\"Bold\\\">Do not</span> mix MOUNJARO with any other medicine.</li><li><span class=\\\"Bold\\\">Do not</span> inject MOUNJARO in the same injection site used for other medicines.</li></ul><table width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"53.250%\\\"/><col align=\\\"left\\\" width=\\\"46.750%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 13: </span><br/>Choose your injection site. <br/> You can inject MOUNJARO under the skin (subcutaneously) of your stomach area (abdomen) or thighs. <br/> Someone else can inject in your stomach area, thighs, or the back of the upper arms.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><a name=\\\"f48\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-16-v1.jpg\\\"/><a name=\\\"f49\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-17-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 14:</span><br/>Insert the needle into your skin.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><a name=\\\"f50\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-18-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 15:</span><br/>Push down on the plunger to inject your dose.          <br/>The needle should stay in your skin for at least 5 seconds to make sure you have injected all of your dose.</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><a name=\\\"f51\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-19-v1.jpg\\\"/></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 16:</span><br/>Pull the needle out of your skin.<br/><ul class=\\\"Disc\\\"><li>If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab. <span class=\\\"Bold\\\">Do not</span> rub the area.</li><li><span class=\\\"Bold\\\">Do not</span> recap the needle. Recapping the needle can lead to a needle stick injury.</li></ul></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><a name=\\\"f52\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"moun-vial-ifu-20-v1.jpg\\\"/></td></tr></tbody></table><p><span class=\\\"Bold\\\">Disposing of used needles and syringes</span></p><ul class=\\\"Disc\\\"><li>Put your used needle and syringe in an FDA-cleared sharps disposal container right away after use. <span class=\\\"Bold\\\">Do not</span> throw away (dispose of) loose needles and syringes in your household trash.</li><li>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:       <dl><dt>-</dt><dd> made of a heavy-duty plastic,</dd><dt>-</dt><dd> can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</dd><dt>-</dt><dd> upright and stable during use,</dd><dt>-</dt><dd> leak-resistant, and</dd><dt>-</dt><dd> properly labeled to warn of hazardous waste inside the container.</dd></dl></li><li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: <br/> http://www.fda.gov/safesharpsdisposal.</li><li><span class=\\\"Bold\\\">Do not</span> dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. <span class=\\\"Bold\\\">Do not</span> recycle your used sharps disposal container.</li></ul><p><span class=\\\"Bold\\\">Storing MOUNJARO</span></p><ul class=\\\"Disc\\\"><li>Store all unopened vials in the refrigerator at 36°F to 46°F (2°C to 8°C).</li><li>You may store the unopened vial at room temperature up to 86°F (30°C) for up to 21 days.</li><li><span class=\\\"Bold\\\">Do not</span> freeze. <span class=\\\"Bold\\\">Do not</span> use if MOUNJARO has been frozen.</li><li>Store the vial in the original carton to protect from light.</li><li>Throw away all opened vials after use, even if there is medicine left in the vial.</li></ul><p><span class=\\\"Bold\\\">Keep MOUNJARO vials, syringes, needles, and all medicines out of the reach of children.</span></p><p>If you have any questions or problems with your MOUNJARO, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help.</p><p><span class=\\\"Bold\\\">Marketed by:<br/> Lilly USA, LLC  <br/> Indianapolis, IN 46285, USA</span></p><p>MOUNJARO is a registered trademark of Eli Lilly and Company.</p><p>Copyright © 2023, 2024, Eli Lilly and Company. All rights reserved.</p><p>MON-VL-0002-IFU-20240229</p><p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p><p>Revised: February 2024</p></section>\",\n            \"mechanismOfAction\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43679-0\\\"><a name=\\\"s53\\\"></a><a name=\\\"section-11.1\\\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\\\"First\\\">Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is an amino-acid sequence including a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.</p><p>Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.</p></section>\",\n            \"contraindications\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34070-3\\\"><a name=\\\"s8\\\"></a><a name=\\\"section-4\\\"></a><p></p><h1>4 CONTRAINDICATIONS</h1><p class=\\\"First\\\">MOUNJARO is contraindicated in patients with:</p><ul class=\\\"Disc\\\"><li>A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s10\\\">5.1</a>)]</span>.</li><li>Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with MOUNJARO <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s13\\\">5.4</a>)]</span>.</li></ul></section>\",\n            \"highlights\": {\n                \"dosageAndAdministration\": \"<div><ul class=\\\"Disc\\\"><li>The recommended starting dosage is 2.5 mg injected subcutaneously once weekly (<a href=\\\"#s5\\\">2.1</a>)</li><li>After 4 weeks, increase to 5 mg injected subcutaneously once weekly (<a href=\\\"#s5\\\">2.1</a>)</li><li>If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.</li><li>The maximum dosage is 15 mg subcutaneously once weekly (<a href=\\\"#s5\\\">2.1</a>).</li><li>Administer once weekly at any time of day, with or without meals. (<a href=\\\"#s6\\\">2.2</a>)</li><li>Inject subcutaneously in the abdomen, thigh, or upper arm. (<a href=\\\"#s6\\\">2.2</a>)</li><li>Rotate injection sites with each dose.</li></ul></div>\"\n            }\n        }\n    },\n    {\n        \"drugName\": \"Jaypirca\",\n        \"setId\": \"bd551845-0878-49a4-860f-839b83f6b801\",\n        \"slug\": \"jaypirca-bd55184\",\n        \"labeler\": \"Lilly\",\n        \"label\": {\n            \"genericName\": \"pirtobrutinib\",\n            \"labelerName\": \"Eli Lilly and Company\",\n            \"productType\": \"HUMAN PRESCRIPTION DRUG LABEL\",\n            \"effectiveTime\": \"20241113\",\n            \"title\": \"JAYPIRCA\",\n            \"indicationsAndUsage\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34067-9\\\"><a name=\\\"s1\\\"></a><a name=\\\"section-1\\\"></a><p></p><h1>1 INDICATIONS AND USAGE</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s2\\\"></a><a name=\\\"section-1.1\\\"></a><p></p><h2>1.1 Mantle Cell Lymphoma</h2><p class=\\\"First\\\">JAYPIRCA<span class=\\\"Sup\\\">®</span> is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.</p><p>This indication is approved under accelerated approval based on response rate <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s63\\\">14.1</a>)].</span> Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s2a\\\"></a><a name=\\\"section-1.2\\\"></a><p></p><h2>1.2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>JAYPIRCA is indicated for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.</p><p>This indication is approved under accelerated approval based on response rate <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s64\\\">14.2</a>)].</span> Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.</p></div></section>\",\n            \"dosageAndAdministration\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34068-7\\\"><a name=\\\"s3\\\"></a><a name=\\\"section-2\\\"></a><p></p><h1>2 DOSAGE AND ADMINISTRATION</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s4\\\"></a><a name=\\\"section-2.1\\\"></a><p></p><h2>2.1 Recommended Dosage</h2><p class=\\\"First\\\">The recommended dosage of JAYPIRCA is 200 mg orally once daily until disease progression or unacceptable toxicity.</p><p>Advise patients of the following:</p><ul class=\\\"Disc\\\"><li>Swallow tablets whole with water. Do not cut, crush, or chew tablets.</li><li>Take JAYPIRCA at the same time each day. JAYPIRCA may be taken with or without food.</li><li>If a dose of JAYPIRCA is missed by more than 12 hours, do not make up the dose and take the next dose as scheduled.</li></ul></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s5\\\"></a><a name=\\\"section-2.2\\\"></a><p></p><h2>2.2 Dosage Modifications for Adverse Reactions</h2><p class=\\\"First\\\">Recommended dosage modifications of JAYPIRCA for adverse reactions are presented in <a href=\\\"#t1\\\">Table 1</a><span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s12\\\">5.1</a>, <a href=\\\"#s13\\\">5.2</a>, <a href=\\\"#s14\\\">5.3</a>, and <a href=\\\"#s15\\\">5.4</a>)]</span>.</p><a name=\\\"t1\\\"></a><table width=\\\"100%\\\"><caption><span>Table 1: Recommended Dosage Modification of JAYPIRCA for Adverse Reactions</span></caption><col align=\\\"left\\\" width=\\\"31.933%\\\"/><col align=\\\"left\\\" width=\\\"23.567%\\\"/><col align=\\\"left\\\" width=\\\"44.500%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Dose modification is not recommended for asymptomatic lymphocytosis. Asymptomatic lipase increase may not necessarily warrant dose modification.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Evaluate the benefit-risk before resuming treatment at the same dose for a Grade 4 non-hematological toxicity.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Adverse Reaction</span></td><td align=\\\"left\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Occurrences Requiring Dosage Modification</span></td><td align=\\\"left\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Modification</span><br/>(Starting Dosage: 200 mg once daily)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" rowspan=\\\"4\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>Grade 3 or greater non-hematologic toxicity <span class=\\\"Sup\\\">a</span></li><li>Absolute neutrophil count &lt; 1 to 0.5 x 10<span class=\\\"Sup\\\">9</span>/L with fever and/or infection</li><li>Absolute neutrophil count &lt; 0.5 x 10<span class=\\\"Sup\\\">9</span>/L lasting 7 or more days</li><li>Platelet count &lt; 50 to 25 x 10<span class=\\\"Sup\\\">9</span>/L with bleeding</li><li>Platelet count &lt; 25 x 10<span class=\\\"Sup\\\">9</span>/L</li></ul></td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">First occurrence</span></td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at original dosage (200 mg once daily)<span class=\\\"Sup\\\">a</span>.</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Second occurrence</span></td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 100 mg once daily.</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Third occurrence</span></td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 50 mg once daily.</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Fourth occurrence</span></td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Discontinue JAYPIRCA.</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s6\\\"></a><a name=\\\"section-2.3\\\"></a><p></p><h2>2.3 Dosage Modifications for Patients with Severe Renal Impairment</h2><p class=\\\"First\\\">For patients with severe renal impairment (eGFR 15-29 mL/min), reduce the JAYPIRCA dose to 100 mg once daily if the current dose is 200 mg once daily otherwise reduce the dose by 50 mg. If the current dosage is 50 mg once daily, discontinue JAYPIRCA <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s42\\\">8.7</a>), Clinical Pharmacology (<a href=\\\"#s48\\\">12.3</a>)]</span>. No dosage adjustment of JAYPIRCA is recommended in patients with mild to moderate renal impairment (eGFR 30-89 mL/min).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s7\\\"></a><a name=\\\"section-2.4\\\"></a><p></p><h2>2.4 Dosage Modifications for Concomitant Use with Strong CYP3A Inhibitors</h2><p class=\\\"First\\\">Avoid concomitant use of strong CYP3A inhibitors with JAYPIRCA <span class=\\\"Italics\\\">[see Drug Interactions (<a href=\\\"#s23\\\">7.1</a>), Clinical Pharmacology (<a href=\\\"#s48\\\">12.3</a>)]</span>. If concomitant use of a strong CYP3A inhibitor is unavoidable, reduce the JAYPIRCA dose by 50 mg. If the current dosage is 50 mg once daily, interrupt JAYPIRCA treatment for the duration of strong CYP3A inhibitor use. After discontinuation of a strong CYP3A inhibitor for 5 half-lives, resume the JAYPIRCA dose that was taken prior to initiating the strong CYP3A inhibitor.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s8\\\"></a><a name=\\\"section-2.5\\\"></a><p></p><h2>2.5 Dosage Modifications for Concomitant Use with CYP3A Inducers</h2><p class=\\\"First\\\">Avoid concomitant use of strong or moderate CYP3A inducers with JAYPIRCA <span class=\\\"Italics\\\">[see Drug Interactions (<a href=\\\"#s23\\\">7.1</a>), Clinical Pharmacology (<a href=\\\"#s48\\\">12.3</a>)]</span>. If concomitant use with moderate CYP3A inducers is unavoidable and the current dosage of JAYPIRCA is 200 mg once daily, increase the dose to 300 mg. If the current dosage is 50 mg or 100 mg once daily, increase the dose by 50 mg.</p></div></section>\",\n            \"dosageFormsAndStrengths\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43678-2\\\"><a name=\\\"s9\\\"></a><a name=\\\"section-3\\\"></a><p></p><h1>3 DOSAGE FORMS AND STRENGTHS</h1><p class=\\\"First\\\">Tablets:</p><p>Each 50 mg tablet is blue, arc-triangle shaped, film-coated, and debossed with “Lilly 50” on one side and “6902” on the other side.</p><p>Each 100 mg tablet is blue, round, film-coated, and debossed with “Lilly 100” on one side and “7026” on the other side.</p></section>\",\n            \"warningsAndPrecautions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43685-7\\\"><a name=\\\"s11\\\"></a><a name=\\\"section-5\\\"></a><p></p><h1>5 WARNINGS AND PRECAUTIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s12\\\"></a><a name=\\\"section-5.1\\\"></a><p></p><h2>5.1 Infections</h2><p class=\\\"First\\\">Fatal and serious infections (including bacterial, viral, or fungal infections) and opportunistic infections have occurred in patients treated with JAYPIRCA. In the clinical trial, Grade 3 or higher infections occurred in 24% of 593 patients, most commonly pneumonia (14%), with fatal infections occurring in 4.4% of patients. Sepsis occurred in 6% of patients and febrile neutropenia in 4%. In patients with CLL/SLL, Grade 3 or higher infections occurred in 32% of patients, with fatal infections occurring in 8%. Opportunistic infections after treatment with JAYPIRCA have included, but are not limited to, <span class=\\\"Italics\\\">Pneumocystis jirovecii</span> pneumonia and fungal infection <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s19\\\">6.1</a>)]</span>.</p><p>Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients who are at increased risk for infections, including opportunistic infections. Monitor patients for signs and symptoms of infection, evaluate promptly, and treat appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s5\\\">2.2</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s13\\\"></a><a name=\\\"section-5.2\\\"></a><p></p><h2>5.2 Hemorrhage</h2><p class=\\\"First\\\">Fatal and serious hemorrhage has occurred with JAYPIRCA. Major hemorrhage (defined as Grade 3 or higher bleeding or any central nervous system bleeding) occurred in 3% of 593 patients treated with JAYPIRCA, including gastrointestinal hemorrhage; fatal hemorrhage occurred in 0.3% of patients. Bleeding of any grade, excluding bruising and petechiae, occurred in 17% of patients <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s19\\\">6.1</a>)]</span>.</p><p>Major hemorrhage occurred in 2.3% of patients taking JAYPIRCA without antithrombotic agents and 0.7% of patients taking JAYPIRCA with antithrombotic agents. Consider the risks and benefits of antithrombotic agents when co-administered with JAYPIRCA. Monitor patients for signs of bleeding. Based on severity of bleeding, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s5\\\">2.2</a>)]</span>.</p><p>Consider the benefit-risk of withholding JAYPIRCA for 3 to 7 days pre- and post-surgery depending upon the type of surgery and risk of bleeding.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s14\\\"></a><a name=\\\"section-5.3\\\"></a><p></p><h2>5.3 Cytopenias</h2><p class=\\\"First\\\">JAYPIRCA can cause cytopenias, including neutropenia, thrombocytopenia, and anemia.</p><p>In the clinical trial, Grade 3 or 4 cytopenias, including decreased neutrophils (26%), decreased platelets (12%), and decreased hemoglobin (12%) developed in patients treated with JAYPIRCA. Grade 4 decreased neutrophils developed in 14% of patients and Grade 4 decreased platelets developed in 6% of patients <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s19\\\">6.1</a>)]</span>.</p><p>Monitor complete blood counts regularly during treatment. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s5\\\">2.2</a>)].</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s15\\\"></a><a name=\\\"section-5.4\\\"></a><p></p><h2>5.4 Cardiac Arrhythmias</h2><p class=\\\"First\\\">Cardiac arrhythmias, including atrial fibrillation and atrial flutter, were reported in recipients of JAYPIRCA. Atrial fibrillation or flutter were reported in 3.2% of patients, with Grade 3 or 4 atrial fibrillation or flutter reported in 1.5% of 593 patients in the clinical trial <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s19\\\">6.1</a>)]</span>. Other serious cardiac arrhythmias such as supraventricular tachycardia and cardiac arrest occurred in 0.5% of patients. Patients with cardiac risk factors, such as hypertension, or previous arrhythmias may be at increased risk.</p><p>Monitor for signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea) and manage appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s5\\\">2.2</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s16\\\"></a><a name=\\\"section-5.5\\\"></a><p></p><h2>5.5 Second Primary Malignancies</h2><p class=\\\"First\\\">Second primary malignancies, including non-skin carcinomas, developed in 9% of 593 patients treated with JAYPIRCA monotherapy. The most frequent malignancy was non-melanoma skin cancer, reported in 4.6% of 593 patients. Other second primary malignancies included solid tumors (including genitourinary and breast cancers) and melanoma. Advise patients to use sun protection and monitor patients for the development of second primary malignancies.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s16a\\\"></a><a name=\\\"section-5.6\\\"></a><p></p><h2 style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>5.6 Hepatotoxicity, Including Drug-Induced Liver Injury</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including JAYPIRCA.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Evaluate bilirubin and transaminases at baseline and throughout treatment with JAYPIRCA. For patients who develop abnormal liver tests after JAYPIRCA, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold JAYPIRCA. Upon confirmation of DILI, discontinue JAYPIRCA.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s17\\\"></a><a name=\\\"section-5.7\\\"></a><p></p><h2>5.7 Embryo-Fetal Toxicity</h2><p class=\\\"First\\\">Based on findings in animals, JAYPIRCA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of pirtobrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity including embryo-fetal mortality and malformations at maternal exposures (AUC) approximately 3-times the recommended dose of 200 mg once daily. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with JAYPIRCA and for one week after the last dose <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s29\\\">8.1</a>, <a href=\\\"#s35\\\">8.3</a>)].</span></p></div></section>\",\n            \"adverseReactions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34084-4\\\"><a name=\\\"s18\\\"></a><a name=\\\"section-6\\\"></a><p></p><h1>6 ADVERSE REACTIONS</h1><p class=\\\"First\\\">The following clinically significant adverse reactions are described elsewhere in the labeling:</p><ul class=\\\"Disc\\\"><li>Infections <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s12\\\">5.1</a>)]</span></li><li>Hemorrhage <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s13\\\">5.2</a>)]</span></li><li>Cytopenias <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s14\\\">5.3</a>)]</span></li><li>Atrial Fibrillation and Atrial Flutter <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s15\\\">5.4</a>)]</span></li><li>Second Primary Malignancies <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s16\\\">5.5</a>)]</span></li><li>Hepatotoxicity, including DILI <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s16a\\\">5.6</a>)]</span></li></ul><div class=\\\"Section\\\" data-sectioncode=\\\"90374-0\\\"><a name=\\\"s19\\\"></a><a name=\\\"section-6.1\\\"></a><p></p><h2>6.1 Clinical Trials Experience</h2><p class=\\\"First\\\">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be compared to rates in the clinical trials of another drug and may not reflect the rates observed in the general patient population.</p><p>The data in the WARNINGS AND PRECAUTIONS reflect exposure to JAYPIRCA as a single-agent, administered at 200 mg once daily in 593 patients with hematologic malignancies in the BRUIN study. Among these 593 patients, the median duration of exposure was 10 months, 62% were exposed for at least 6 months and 45% were exposed for at least one year.</p><p>In this pooled safety population, the most common (≥ 20%) adverse reactions, including laboratory abnormalities, were decreased neutrophil count (46%), decreased hemoglobin (39%), fatigue (32%), decreased lymphocyte count (31%), musculoskeletal pain (30%), decreased platelet count (29%), diarrhea (24%), COVID-19 (22%), bruising (21%), and cough (20%).</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s19a\\\"></a><a name=\\\"section-6.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Mantle Cell Lymphoma</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s19b\\\"></a><a name=\\\"section-6.1.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">BRUIN</span></p><p>The safety of JAYPIRCA was evaluated in the BRUIN trial in patients with MCL who received a prior BTK inhibitor <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s63\\\">14.1</a></span>)<span class=\\\"Italics\\\">]</span>. The trial required a platelet count ≥ 50 x 10<span class=\\\"Sup\\\">9</span>/L, absolute neutrophil count ≥ 0.75 x 10<span class=\\\"Sup\\\">9</span>/L, hepatic transaminases ≤ 2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with active central nervous system (CNS) involvement by lymphoma, significant cardiovascular disease, major bleeding or grade ≥ 3 arrhythmia with a prior BTK inhibitor, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor.</p><p>Patients received JAYPIRCA 200 mg orally once daily until disease progression or unacceptable toxicity (n = 128); 36% were exposed for 6 months or longer and 10% were exposed for at least one year. The median number of prior therapies was 3 (range: 1-9). The median age was 71 years (range: 46 to 88 years) and 80% of patients were male. Race was reported for all patients; 78% were White, 14% were Asian, 2.3% were Black, and 2.3% were Hispanic or Latino.</p><p>Serious adverse reactions occurred in 38% of patients who received JAYPIRCA. Serious adverse reactions that occurred in ≥ 2% of patients were pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%). Fatal adverse reactions within 28 days of the last dose of JAYPIRCA occurred in 7% of patients, most commonly due to infections (4.7%) including COVID-19 (3.1% of all patients).</p><p>Adverse reactions led to dose reductions in 4.7%, treatment interruption in 32%, and permanent discontinuation of JAYPIRCA in 9%. Adverse reactions that resulted in dosage modification in &gt; 5% of patients included pneumonia and neutropenia. Adverse reactions which resulted in permanent discontinuation of JAYPIRCA in &gt; 1% of patients included pneumonia.</p><p>The most common adverse reactions (≥ 15%), excluding laboratory terms, were fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising.</p><p><a href=\\\"#t2\\\">Table 2</a> summarizes select adverse reactions in BRUIN.</p><a name=\\\"t2\\\"></a><table width=\\\"100%\\\"><caption><span>Table 2: Adverse Reactions (≥ 10%) in Patients with MCL Who Received JAYPIRCA</span></caption><col align=\\\"left\\\" width=\\\"37.467%\\\"/><col align=\\\"left\\\" width=\\\"31.267%\\\"/><col align=\\\"left\\\" width=\\\"31.267%\\\"/><thead><tr class=\\\"First\\\"><th align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"top\\\"></th><th align=\\\"center\\\" class=\\\"Botru"